| Compounds | Topics | Title | Date |
|---|---|---|---|
| Terpinolene | cancer in vitro | Terpinolene, a component of herbal sage, downregulates AKT1 expression in K562 cells | Nov 2011 |
|
Action Pathway: AKT1 Terpinolene markedly reduced the protein expression of AKT1; however, linalool or carnosol did not downregulate it. | |||
| Terpinolene | anti-oxidant in vitro | The monoterpene terpinolene from the oil of Pinus mugo L. in concert with alpha-tocopherol and beta-carotene effectively prevents oxidation of LDL. | Jun 2005 |
|
Ingestion Method: essential oil of Pinus mugo The essential oil of Pinus mugo and the contained monoterpene terpinolene effectively prevent low-density lipoprotein (LDL)-oxidation | |||
| Terpinolene | sedative in mice via experiment | Sedative effects of vapor inhalation of the essential oil of Microtoena patchoulii and its related compounds. | Jan 2013 |
|
Ingestion Method: inhaled Elongation of sleeping time induced by pentobarbital was further elongated by the inhalation of terpinolene, but not by that of 1-octen-3-ol. It is indicated that terpinolene is a potent suppressor of the central nervous system. | |||
| Phellandrene,Terpinolene,Cymene,Pinene | cancer, anti-inflamatory,cancer,breast cancer in vitro | Chemical composition, antimicrobial, and cytotoxicity studies on S. erianthum and S. macranthum essential oils | Apr 2012 |
| The Solanum essential oils possess strong antimicrobial activity in addition to the potent cytotoxic potential of S. erianthum leaf oil against Hs 578T and PC-3 cells. | |||
| Terpinolene | anti-oxidant,cancer in vitro | Anticancer and anti-oxidant properties of terpinolene in rat brain cells. | Sept 2013 |
|
Ingestion Method: 50-100mg/L Our findings clearly demonstrate that TPO is a potent antiproliferative agent for brain tumour cells and may have potential as an anticancer agent, which needs to be further studied. | |||
| Terpinolene | anti-oxidant in vitro | Genotoxic and oxidative damage potentials in human lymphocytes after exposure to terpinolene in vitro. | May 2015 |
| Again, TPO (at 10, 25, 50 and 75 mg/L) treatment caused statistically important (p < 0.05) increases of TAC levels in human lymphocytes without changing TOS levels. In conclusion, TPO can be a new resource of therapeutics as recognized in this study with its non-genotoxic and antioxidant features. | |||